BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
Want to see TSE:BCT full AI Analyst Report?
BCT Stock Chart & Stats
C$10.64
-C$0.02(-3.08%)
At close: 4:00 PM EST
C$10.64
-C$0.02(-3.08%)
Day’s Range― - ―
52-Week RangeC$4.13 - C$49.00
Previous CloseN/A
Volume105.15K
Average Volume (3M)3.11K
Market Cap
C$37.50M
Enterprise Value-C$22.79M
Total Cash (Recent Filing)C$29.65M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.61
Shares Outstanding8,699,787
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure and repaired equity base provide durable financial flexibility for a clinical-stage biotech. Lower leverage reduces refinancing and bankruptcy risk, lets management prioritize R&D or partnerships, and preserves strategic optionality when raising capital.
Focused Immunotherapy PipelineA concentrated R&D focus on cell- and immune-based therapies (lead Bria-IMT) creates durable scientific specialization and program optionality. Focused therapeutic niche and combination approaches can build high barriers to entry and create long-term competitive differentiation in breast cancer immunotherapy.
Lean Operating ModelA very small employee base implies a lean cost structure, concentrating capital on clinical development rather than overhead. Structurally, lower fixed costs improve operational agility and can stretch available funding to support trial milestones longer than higher-overhead peers.
Bears Say
High Cash BurnSustained negative operating and free cash flow (~-37M TTM) indicates the company is consuming capital to advance trials. This persistent burn erodes cash reserves, increases probability of future financings, and constrains strategic flexibility over the medium term.
No Revenue; Widening LossesAbsent commercial revenue and materially widening net losses (TTM ~45.8M) mean the business cannot self-fund development. The structural loss profile raises uncertainty around eventual profitability and heightens reliance on external capital to sustain programs.
Reliance On External FundingRising cash burn and no commercial cashflows make the company dependent on capital markets or partners. Structurally, this exposure creates dilution and execution risk: funding gaps or adverse market conditions can delay trials, change development timelines, or force unfavorable deals.
BriaCell Therapeutics News
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$4.13 and its highest was C$49.00 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$37.50M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Jun 17, 2026 which is in 9 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Mar 10, 2026. The company reported -C$3.575 earnings per share for the quarter, missing the consensus estimate of N/A by -C$3.575.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 8,699,787 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$3.575 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.914%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.49%
12-Months-Change
Fundamentals
Return on Equity
-221.75%
Trailing 12-Months
Asset Growth
235.47%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---